Herantis Pharma

17 articles about Herantis Pharma

• Nanoform and Herantis sign Biologics Proof of Concept Agreement

  2/9/2021

  Nanoform Finland Plc and Herantis Pharma Plc announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects aiming to enhance nasal drug delivery to the brain of Herantis' CDNF therapies for Parkinson's disease using Nanoform's proprietary biological nanoparticle technology.

• Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

  2/25/2020

  HELSINKI , Feb. 25, 2020 /PRNewswire/ -- Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses as measured by PET imaging in some patients. Results from the second part of trial, in which all patients will receive CDNF for an additional six months, are expected in Q3 2020. H

• Herantis Pharma Plc Completes Patient Recruitment and Treatment in Phase 2 AdeLE Trial in Breast Cancer Associated Lymphedema

  12/17/2019

  Herantis Pharma Plc announced that patient recruitment in the Company's Phase 2 clinical trial AdeLE has been completed.

• Herantis Pharma Strengthens Team - Outi Lahdenperä and Antti Vuolanto Have Joined Herantis

  2/12/2018

  The company has strengthened its core team with two experienced drug development professionals.

• Herantis Pharma Completes Patient Enrolment in Phase I Study of Lymfactin Gene Therapy for Secondary Lymphedema and Has Submitted Phase II Application

  2/8/2018

  The company intends to proceed rapidly to a randomized, placebo-controlled Phase 2 study of Lymfactin in the same indication and has already submitted the clinical trial application to the regulatory authorities.

• Herantis Pharma Expands on Timeline for Lymfactin Studies

  12/27/2017

  Patient recruitment is expected to be completed in the first quarter of 2018 instead of by the end of 2017 as previously estimated and announced.

• Herantis Pharma’s Financial Reporting Schedule and Annual General Meeting in 2018

  12/4/2017

  Financial Statements bulletin in regard to 2017 on Friday the 2nd of March 2018 .

• Decisions of Herantis Pharma Plc's Extraordinary General Meeting of Shareholders

  11/9/2017

  The Extraordinary General Meeting of Shareholders resolved to authorise the Board of Directors, as proposed by the Board of Directors, to decide on the issuance of shares.

• Notice to Convene Herantis Pharma Plc's Extraordinary General Meeting of Shareholders

  10/19/2017

  Shareholders of Herantis Pharma are invited to attend an Extraordinary General Meeting of the Company on Thursday, 9 November 2017.

• Herantis Pharma Has Initiated Patient Recruitment And Consented First Patient In CDNF Study In Parkinson's Disease

  9/27/2017

• Herantis Pharma's Half Year Financial Report January 1 - June 30, 2017 (Unaudited)

  8/29/2017

• Herantis Pharma's Manager's Transactions

  8/22/2017

• Herantis Pharma's Lymfactin Study Advances To Last Patient Cohort, Company Announces Initial Plans For Continued Development

  6/22/2017

• Herantis Pharma's Clinical Study With CDNF In Parkinson's Disease Authorized In Finland, Company Expands On Development Plan

  6/12/2017

• Herantis Pharma Granted A U.S. Patent On Therapeutic Use Of MANF

  5/23/2017

• Herantis Pharma's Clinical Study With Lymfactin Advances To High Dose Level

  3/7/2017

• Herantis Pharma's Phase 2 Dry Eye Study Recruitment Completed Ahead Of Schedule

  3/11/2015